Caris Life Sciences CAI 深 沪
已收盘 08-21 16:00:00 美东时间
26.27
+1.690
+6.88%
华盛通- 最 高26.60
- 今 开24.73
- 成交量 638.93万股
- 最 低 24.32
- 昨 收 24.58
- 总市值 74.24亿
- 52周最高 38.68
- 市盈率 静 --
- 换手率 2.26%
- 52周最低 14.19
- 委 比 -89.53%
- 总股本 2.83亿
- 历史最高 42.50
- 量 比 1.40
- 振 幅 9.28%
- 历史最低 14.19
- 每 手 1
- 风险率 6.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Deere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling around 300 points on Thursday. Shares of Deere & Co (NYSE:DE) gained during Thursday’s session after the company reported better-than-expected second-quarter financial results and raised its full-year net income outlook. Earnings of $5.10 per ...
08-20 23:06
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26
Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and raises the price target from $25 to $26.
08-06 22:51
美股夜盘 | SiTime Corporation暴升32.41%，SoundHound AI暴升23.17%
SiTime Corporation暴升32.41%；SoundHound AI暴升23.17%；Caris Life Sciences劲升12.22%
08-06 15:01
美股夜盘 | SiTime Corporation暴升32.82%，SoundHound AI暴升24.57%
SiTime Corporation暴升32.82%；SoundHound AI暴升24.57%；Paycom Software劲升13.17%
08-06 13:01
美股夜盘 | SiTime Corporation暴升30.73%，SoundHound AI暴升21.15%
SiTime Corporation暴升30.73%；SoundHound AI暴升21.15%；Caris Life Sciences劲升12.46%
08-06 10:01
美股夜盘 | SiTime Corporation暴升33.24%，SoundHound AI暴升21.46%
SiTime Corporation暴升33.24%；SoundHound AI暴升21.46%；Caris Life Sciences劲升13.37%
08-06 09:01
Caris Life Sciences To Offer In-House PTEN Immunohistochemistry Testing After Recent FDA Approval Of Biomarker-Guided Therapy And Diagnostic Assay
This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representin...
07-14 20:36
